Excellent post Sector, Thank you. Can I just add to this that EX1 are extracting Exosomes from platelets, so a blood product, which is far less invasive than harvesting from bone marrow.
I think 2019 is going to be a very exciting year & GMP will be necessary to move forward. It appears they already have the extraction process & stability of product worked out. This has been one of the issues with stem cell treatment from reading. It’s a new area for me also. But very happy to be here. Aussie Biotechs are really on the cutting edge of research & development, and somewhat undervalued, which never ceases to amaze me.
The selling: I guess at 120% from IPO that’s tempting especially just before Xmas, we could all probably do with a short spell in the tropics. This one’s a keeper though. GLTAH
